09/30/2022

ALS Drug Wins FDA Approval Despite Questionable Data

This approval provides another important treatment option

A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.

The Food and Drug Administration (FDA) approved the drug from Amylyx Pharmaceuticals based on results from one small, mid-stage study in which patients with the debilitating disease appeared to progress more slowly and survive several months longer. Typically, the FDA requires two large studies or one study with “very persuasive” survival results for approval.

“This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” FDA’s neurology drug director Dr. Billy Dunn said in a statement.

Please select this link to read the complete article from The Associated Press.